Stock Analiz

Starling Oncology, Inc. (STLN) stock forecast and price target

Price $3.50 · data as of November 13, 2026

12-month price target

Average target$9.25
Upside / downside+164.3%
Analysts4
ConsensusStrong buy
Low $8.00Average $9.25High $10.00

Gold marker: average target · white marker: today’s price ($3.50)

Analyst ratings

Strong buy 1Buy 3Hold 0Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-0.27—$656M
Next fiscal year
ends December 31, 2027
$-0.09—$875M
Next quarter
ends December 31, 2026
$-0.04—$178M
Quarter after
ends March 31, 2027
$-0.05—$198M

Consensus of the analysts covering Starling Oncology, updated daily. In the last 30 days 0 estimates were raised and 4 lowered.

Our model vs. Wall Street

Analysts see 164.3% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Starling Oncology’s intrinsic value about 131% above today’s market value, and it scores 2.0 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Starling Oncology stock price target?

The average 12-month target from 4 analysts is $9.25, 164.3% above the current price of $3.50 Targets range from $8.00 to $10.00.

Is Starling Oncology a buy according to analysts?

The consensus rating is “Strong buy” (1 strong buy, 3 buy). Ratings are opinions, not guarantees; this is not investment advice.

How much is Starling Oncology expected to earn?

Analysts expect EPS of $-0.27 for the fiscal year ending December 31, 2026 and $-0.09 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.